Tuesday, September 10, 2019 10:44:22 AM
[ACCESSWIRE]
ACCESSWIRESeptember 10, 2019
ANN ARBOR, MICHIGAN / ACCESSWIRE / September 10, 2019 / ENDRA Life Sciences Inc. (“ENDRA”) (NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS™), will attend the EASL Nonalcoholic Fatty Liver Disease (NAFLD) Summit in Seville, Spain, on September 26-28, 2019.
The summit will be hosted by EASL, The European Association for the Study of the Liver, which is a medical association dedicated to pursuing excellence in liver research and clinical practice of liver disorders. At Booth #4, ENDRA will highlight the R&D status of its TAEUS™ liver application and findings for Part B of the Robarts Research Institute liver fat feasibility study. The findings from this study are expected to be submitted for publication in a peer reviewed journal and presented at scientific meetings by the Study Investigators at the Robarts Research Institute. The study is registered on the National Institute of Health database of global clinical studies here.
Renaud Maloberti, CCO of ENDRA Life Sciences, said: “Attending key clinical conferences, such as the EASL NAFLD Summit, is a central component of ENDRA’s pre-commercialization strategy for the TAEUS liver application. ENDRA’s EASL booth and staff will have a front-line opportunity to engage hepatologists, gastroenterologists and endocrinologists, and raise awareness for the TAEUS liver application in Europe. Additionally, our presence will help grow our global list of interested liver disease clinicians and develop relationships for a phased launch of the TAEUS application planned for 2020,” concluded Maloberti.
Michael Thornton, ENDRA’s CTO, added: “Beyond the commercial value, attending NAFLD-focused meetings like EASL enables us to collect valuable first-hand feedback on ENDRA’s technology, better understand the evolving clinical interest in NAFLD, and the need for our TAEUS liver application from clinicians. We are also looking forward to sharing the clinical feedback and findings derived from the first-in-human TAEUS study conducted by researchers at the Robarts Research Institute. This feasibility study has allowed us to develop a clinical workflow for our fatty liver application, provided feedback that is driving product design ergonomics, and allowed us to evaluate quantitative algorithms, all of which is being leveraged as design inputs for our commercial TAEUS product. We believe our pioneering TAEUS technology is well positioned to meet the growing need for a non-invasive, point of care, cost effective tool; aiding in the clinical management of NAFLD. We look forward to sharing our progress with Summit attendees later this month,” concluded Thornton.
About ENDRA Life Sciences Inc.
ENDRA Life Sciences is the pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS™), a ground-breaking technology that visualizes tissue like CT or MRI, but at 50X lower cost, at the point of patient care. TAEUS is designed to work in concert with one million ultrasound systems in global use today. TAEUS is initially focused on the measurement of fat in the liver, as a means to assess and monitor NAFLD and NASH, chronic liver conditions that affect over 1 billion people globally, and for which there are no practical diagnostic tools. Beyond the liver, ENDRA is exploring several other clinical applications of TAEUS, including visualization of tissue temperature during energy-based surgical procedures. www.endrainc.com
About EASL
The European Association for the Study of the Liver(EASL) started as a small group of 70 hepatologists from 15 European countries who came together to share best medical practice in April 1966.Over half a century later EASL has evolved into a major European Association with international influence dedicated to the liver and liver disease. EASL has over 4,000 members from all over the world and provides an annual platform, The International Liver Congress™, for 11,000 liver experts to meet and discuss the latest scientific research. EASL has given rise to many international clinical trials and research collaborations to the benefit of patients all over the world.
About Non-Alcoholic Fatty Liver Disease (NAFLD)
NAFLD is a condition closely associated with obesity, diabetes, hepatitis-C and certain genetic predispositions in which fat accumulates in the liver. NAFLD affects over 1 billion people globally and is estimated to cost the U.S healthcare system over $100 billion annually. NAFLD is often asymptomatic and if left untreated, NAFLD can progress to inflammation (NASH), tissue scarring (fibrosis), cell death (cirrhosis) and liver cancer. By 2025, NAFLD is forecast to be the greatest root cause of liver transplants. The only tools currently available for diagnosing and monitoring NAFLD are impractical: expensive Magnetic Resonance Imaging (MRI) or an invasive surgical biopsy.
"The Investors's Chief Problem--and even his worst enemy--is likely to be himself"
---Benjamin Graham
Recent NDRA News
- Form 8-K - Current report • Edgar (US Regulatory) • 05/10/2024 09:18:05 PM
- Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 05/10/2024 09:17:00 PM
- ENDRA Life Sciences to Report First Quarter 2024 Financial Results on May 14, 2024 • Business Wire • 05/07/2024 12:00:00 PM
- ENDRA Life Sciences Strengthens Intellectual Property with Issuance of Five New International Patents • Business Wire • 05/02/2024 12:00:00 PM
- ENDRA Life Sciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update • Business Wire • 03/28/2024 08:05:00 PM
- ENDRA Life Sciences to Report Fourth Quarter 2023 Financial Results on March 28, 2024 • Business Wire • 03/21/2024 12:00:00 PM
- ENDRA Life Sciences Installs First TAEUS System in the UK • Business Wire • 02/27/2024 01:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/23/2024 10:00:45 PM
- New ICD-10-CM Code by the World Health Organization Paves the Way for Improved NAFLD Diagnostics Including ENDRA Life Sciences’ TAEUS System • Business Wire • 02/21/2024 01:00:00 PM
- ENDRA Life Sciences Bolsters TAEUS® System Intellectual Property with New Patents in U.S., China and Europe • Business Wire • 02/14/2024 01:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 12/29/2023 10:07:32 PM
- ENDRA Life Sciences Secures 39th U.S. Patent for TAEUS® System Technology • Business Wire • 11/29/2023 01:00:00 PM
- ENDRA Life Sciences to Participate in The Benchmark Company’s 12th Annual Discovery One-on-One Investor Conference • Business Wire • 11/27/2023 01:00:00 PM
- ENDRA Life Sciences Reports Third Quarter 2023 Financial Results and Provides Business Update • Business Wire • 11/14/2023 09:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/14/2023 09:02:23 PM
- ENDRA Life Sciences Achieves Intellectual Property Milestone with Issuance of Three New Patents • Business Wire • 11/08/2023 01:00:00 PM
- ENDRA Life Sciences to Report Third Quarter 2023 Financial Results on November 14, 2023 • Business Wire • 11/07/2023 09:05:00 PM
- ENDRA to Host Multidisciplinary Clinical Discussion on Managing Liver Disease During AASLD’s The Liver Meeting® 2023 • Business Wire • 11/06/2023 01:00:00 PM
- Abstract for ENDRA Life Sciences' TAEUS System Accepted for Presentation at EASL Steatotic Liver Disease Summit 2023 • Business Wire • 09/07/2023 12:00:00 PM
- ENDRA Life Sciences' TAEUS De Novo Submission Advances to Next Stage of Review with FDA • Business Wire • 08/30/2023 12:00:00 PM
- ENDRA Life Sciences Expands Intellectual Property with Issuance of U.S. and European Patents • Business Wire • 08/23/2023 12:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2023 08:45:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/14/2023 08:13:52 PM
- ENDRA Life Sciences Reports Second Quarter 2023 Financial Results and Provides a Business Update • Business Wire • 08/14/2023 08:05:00 PM
Avant Technologies Equipping AI-Managed Data Center with High Performance Computing Systems • AVAI • May 10, 2024 8:00 AM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM